shown that patients with nonmuscle invasive bladder cancer (NMIBC) and specifically CIS who fail BCG and progress to muscle Invasive bladder cancer (secondary MIBC) do worse after radical cystectomy (RC) than patients who present with de-novo MIBC. We have previously demonstrated favorable results in a highly selected cohort of patients with clinical complete response (cCR) after neoadjuvant platinumbased chemotherapy (NAC) who forego radical cystectomy (RC) and are placed on an active surveillance and delayed intervention (ASDI) protocol. We sought to investigate whether secondary MIBC or CIS on pre-NAC TUR had worse outcomes than de-novo MIBC in our ASDI cohort.
INTRODUCTION AND OBJECTIVES: Prior studies have
shown that patients with nonmuscle invasive bladder cancer (NMIBC) and specifically CIS who fail BCG and progress to muscle Invasive bladder cancer (secondary MIBC) do worse after radical cystectomy (RC) than patients who present with de-novo MIBC. We have previously demonstrated favorable results in a highly selected cohort of patients with clinical complete response (cCR) after neoadjuvant platinumbased chemotherapy (NAC) who forego radical cystectomy (RC) and are placed on an active surveillance and delayed intervention (ASDI) protocol. We sought to investigate whether secondary MIBC or CIS on pre-NAC TUR had worse outcomes than de-novo MIBC in our ASDI cohort.
METHODS: A single institution IRB-approved urologic oncology database was retrospectively reviewed to identify secondary MIBC and CIS in a cohort of 52 cCR response ASDI patients. A cCR to NAC was defined as negative TURBT, urine cytology, and cross-sectional imaging. Patients on the ASDI protocol were followed with cystoscopy, urine cytology, and cross-sectional imaging at 3-4 month intervals. Kaplan Meier curves and cox regression models were used to identify predictors of recurrence.
RESULTS: Secondary MIBC was identified in 14/52 (26.9%) within the ASDI cohorteall but 1 had documented prior BCG treatment. CIS was present within 21/52 (40%) of pre-NAC TUR specimens. Recurrence risk was similar when stratifying by secondary MIBC vs de-novo MIBC but trended towards increased recurrence risk when stratified by CIS (HR 1.76, p [ 0.111, figure 1) . 5-year cancerspecific, overall, and cystectomy-free survival were similar between groups at 85%, 81% and 60%, respectively. 13/31 (42%) of recurrences were managed conservatively while the remainder underwent RC. On multivariable cox regression controlling for age and hydronephrosis, secondary MIBC was not a significant predictor (HR 0.426, p [ 0.15) , but CIS (HR 2.7, p [ 0.012) and hydronephrosis (HR 2.9, p [ 0.022) both increased risk of relapse.
CONCLUSIONS: While recent studies have suggested that secondary MIBC may be less chemosensitive than de-novo MIBC, when secondary MIBC completely responds to NAC, outcomes on the ASDI protocol are similar. A diagnosis of CIS on pre-NAC TURBT warrants heightened vigilance for recurrence should the patient pursue bladder preservation. METHODS: In this retrospective study from a tertiary university hospital, we identified 469 patients who underwent RC from 2010 to 2016. Patient cohorts were stratified by presence of LVI on TURBT prior to RC. Clinical variables evaluated included age, BMI, CCI, receipt of neoadjuvant chemotherapy (NAC), 30 day complication rates, pathological upstaging, LNP at time of RC, lymph node yield, and final pathological stage. Chi-square test of independence was used to test for associations between LVI and clinical variables. Overall survival (OS) and disease-free survival (DFS) were calculated with KaplanMeier method.
RESULTS: 62 patients were found to have LVI present on TURBT and 407 patients had either no LVI or no mention of LVI on pathology report. Results are summarized in figure 1. Pathological upstaging occurred in 64.5% of the LVI group and 45.7% of the no LVI group (p[0.006) and LNP at RC was identified in 46.8% of the LVI group and 23.4% of the no LVI group (p<0.001). Final pathologic stage was overall higher in the LVI group with 77.5% having !pT2 compared to 59.5% in the no LVI group (p<0.001). Multivariate analysis demonstrated that LVI was independently associated with probability of upstaging (OR: 2.31, 95% CI: 1.30 e 4.09, p[0.004) and LNP (OR: 1.97, 95% CI: 1.04 e 3.71, p[0.037). Further, there was a significant decrease found in OS and DFS for patients with LVI present on TURBT, (p<0.001).
CONCLUSIONS: Patients with LVI at time of TURBT had higher risk for LN positive disease and pathologic upstaging at time of RC. Further, LVI was associated with worse OS and DFS. These results suggest that patients with LVI at time of TURBT may benefit from more aggressive therapy, such as early RC, or receipt of NAC independent of stage. Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e1023
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